WallStSmart

Brookfield Asset Management Ltd. (BAM)vsBlackRock Health Sciences Trust II (BMEZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BAM leads profitability with a 48.9% profit margin vs 0.0%. BMEZ trades at a lower P/E of 4.8x. BAM earns a higher WallStSmart Score of 77/100 (B+).

BAM

Strong Buy

77

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 5.7Quality: 4.0
Piotroski: 2/9Altman Z: 1.97

BMEZ

Avoid

32

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAM5 strengths · Avg: 9.4/10
Profit MarginProfitability
48.9%10/10

Keeps 49 of every $100 in revenue as profit

Operating MarginProfitability
68.7%10/10

Strong operational efficiency at 68.7%

Revenue GrowthGrowth
60.8%10/10

Revenue surging 60.8% year-over-year

Market CapQuality
$75.49B9/10

Large-cap with strong market position

EPS GrowthGrowth
47.4%8/10

Earnings expanding 47.4% YoY

BMEZ2 strengths · Avg: 10.0/10
P/E RatioValuation
4.8x10/10

Attractively priced relative to earnings

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

BAM4 concerns · Avg: 3.8/10
P/E RatioValuation
27.2x4/10

Moderate valuation

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

BMEZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.03B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BAM

The strongest argument for BAM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 48.9% and operating margin at 68.7%. Revenue growth of 60.8% demonstrates continued momentum.

Bull Case : BMEZ

The strongest argument for BMEZ centers on P/E Ratio, Debt/Equity.

Bear Case : BAM

The primary concerns for BAM are P/E Ratio, Price/Book, Altman Z-Score. Debt-to-equity of 5.69 is elevated, increasing financial risk.

Bear Case : BMEZ

The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BAM profiles as a growth stock while BMEZ is a value play — different risk/reward profiles.

BAM is growing revenue faster at 60.8% — sustainability is the question.

BAM generates stronger free cash flow (393M), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BAM scores higher overall (77/100 vs 32/100), backed by strong 48.9% margins and 60.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Asset Management Ltd.

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Brookfield Asset Management is a leading global alternative asset manager and one of the largest investors in real assets.

Visit Website →

BlackRock Health Sciences Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund that focuses on delivering high total returns through a diversified portfolio primarily concentrated in the health sciences sector, which encompasses pharmaceuticals, biotechnology, and medical devices. Capitalizing on BlackRock's extensive industry knowledge, BMEZ targets significant growth opportunities driven by demographic shifts and increasing healthcare spending. With its disciplined investment approach and commitment to funding innovative healthcare solutions, BMEZ provides institutional investors a compelling avenue for portfolio enhancement in a dynamic and rapidly evolving market landscape.

Want to dig deeper into these stocks?